Recombinant oncolytic virus and use thereof

Abstract

Provided are a recombinant oncolytic virus and a use thereof. The recombinant oncolytic virus includes an M protein and an antigen encoded by an exogenous gene, wherein the M protein includes the following site mutations compared to an amino acid sequence as shown in SEQ ID NO 1: mutating of methionine at position 51 into arginine (M51R); mutating of valine at position 221 into phenylalanine (V221F); and mutating of serine at position 226 into arginine (S226R). The recombinant oncolytic viruses provided have better infective ability and killing ability in vitro to abnormally proliferative (tumor) LLC cell and are all not easy to eliminate in the LLC cell, greatly reducing the infective ability of the recombinant oncolytic viruses to normal cells.

Dependencies are inferred from the claim text.